Evogene Ltd.(EVGN)Earnings, Financials & Key Ratios
EVGN•NASDAQ
Price updated Jun 19, 2026
AboutEvogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.Show more
- Revenue$4M-30.9%
- EBITDA-$13M+26.0%
- Net Income-$8M+48.5%
- EPS (Diluted)-1.08+62.6%
- Gross Margin-6.25%-110.9%
- EBITDA Margin-334.54%-7.1%
- Operating Margin-364.24%-8.0%
- Net Margin-220.22%+25.5%
- ROE-63.29%+16.5%
EVGN Key Insights
Evogene Ltd. (EVGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 18.3%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 29.9%
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 38.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EVGN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVGN Price & Volume
Evogene Ltd. (EVGN) stock price & volume — 10-year historical chart
Loading chart...
EVGN Growth Metrics
Evogene Ltd. (EVGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-10.06%
5 Years29.94%
3 Years32.01%
TTM-16.2%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM9.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.27%
Return on Capital
10 Years-42.5%
5 Years-54.16%
3 Years-59.62%
Last Year-74.31%
EVGN Recent Earnings
Evogene Ltd. (EVGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (45%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 20, 2026Metric
Actual
Est
EPS
$0.60-122.2%
$0.27
Rev
$334,000-4.6%
$350,000
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.61-134.6%
$0.26
Rev
$314,000+14.2%
$275,000
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.31-19.2%
$0.26
Rev
$312,000+13.5%
$275,000
Q3 2025
Aug 28, 2025Metric
Actual
Est
EPS
$1.06
—
Rev
$884,000
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.60vs $0.27-122.2% | $334,000vs $350,000-4.6% |
| Q2 2026 | Mar 5, 2026 | $0.61vs $0.26-134.6% | $314,000vs $275,000+14.2% |
| Q4 2025 | Nov 20, 2025 | $0.31vs $0.26-19.2% | $312,000vs $275,000+13.5% |
| Q3 2025 | Aug 28, 2025 | $1.06 | $884,000 |
Based on last 12 quarters of dataView full earnings history →
EVGN Peer Comparison
Evogene Ltd. (EVGN) competitors in Microbiome and Phage Therapeutics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PGEN | 1.45B | 4.82 | -3.42 | 146.73% | -6.47% | -17.69% | 0.24 | |
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 NTRA | 33.14B | 231.41 | -152.24 | 35.9% | -9.05% | -15.13% | 0.13 | |
 CTVA | 52.74B | 78.56 | 49.10 | 2.92% | 6.5% | 4.62% | 0.11 | |
 FMC | 1.44B | 11.55 | -0.65 | -18.34% | -72.93% | -82.27% | 2.00 | |
 AMGN | 182.2B | 337.60 | 23.72 | 9.92% | 20.95% | 89.41% | 6.31 | |
 BIIB | 29.02B | 196.58 | 22.26 | 1.39% | 13.92% | 7.55% | 0.38 | |
 NVAX | 1.5B | 9.13 | 3.59 | 64.69% | -14.73% |
Compare EVGN vs Peers
Evogene Ltd. (EVGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVGN Income Statement
Evogene Ltd. (EVGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.38M | 1.75M | 753K | 1.04M | 930K | 1.68M | 2.98M | 5.58M | 3.85M | 5.36M |
Revenue Growth % | -48.3% | -48.33% | -56.9% | 38.11% | -10.58% | 80.11% | 78.03% | 87.02% | -30.91% | -16.2% |
Cost of Goods Sold | 2.85M | 1.45M | 334K | 574K | 767K | 909K | 1.49M | 2.38M | 4.09M | 6.67M |
COGS % of Revenue | 84.15% | 83.11% | 44.36% | 55.19% | 82.47% | 54.27% | 49.97% | 42.68% | 106.25% | - |
Gross Profit | 536K▲ 0% | 295K▼ 45.0% | 419K▲ 42.0% | 466K▲ 11.2% | 163K▼ 65.0% | 766K▲ 369.9% | 1.49M▲ 94.8% | 3.2M▲ 114.3% | -241K▼ 107.5% | -1.31M▲ 0% |
Gross Margin % | 15.85% | 16.89% | 55.64% | 44.81% | 17.53% | 45.73% | 50.03% | 57.32% | -6.25% | -24.39% |
Gross Profit Growth % | -40.51% | -44.96% | 42.03% | 11.22% | -65.02% | 369.94% | 94.78% | 114.28% | -107.54% | - |
Operating Expenses | 22.48M | 20.28M | 21.59M | 25.28M | 31.12M | 27.71M | 23.72M | 22M | 13.79M | 23.73M |
OpEx % of Revenue | 664.98% | 1161.08% | 2866.53% | 2430.77% | 3345.81% | 1654.15% | 795.54% | 394.5% | 357.98% | - |
Selling, General & Admin | 5.5M | 5.6M | 5.79M | 7.99M | 9.99M | 10.41M | 7.53M | 8.98M | 5.76M | 9.95M |
SG&A % of Revenue | 162.56% | 320.44% | 769.46% | 768.56% | 1074.3% | 621.79% | 252.41% | 160.95% | 149.55% | - |
Research & Development | 16.99M | 14.69M | 15.79M | 17.29M | 21.13M | 20.79M | 16.2M | 12.51M | 7.99M | 13.52M |
R&D % of Revenue | 502.43% | 840.64% | 2097.08% | 1662.21% | 2271.51% | 1241.31% | 543.13% | 224.33% | 207.47% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -3.5M | 0 | 514K | 37K | 265K |
Operating Income | -21.95M▲ 0% | -19.99M▲ 8.9% | -21.17M▼ 5.9% | -24.81M▼ 17.2% | -30.95M▼ 24.7% | -26.94M▲ 13.0% | -22.23M▲ 17.5% | -18.8M▲ 15.4% | -14.03M▲ 25.4% | -25.04M▲ 0% |
Operating Margin % | -649.13% | -1144.19% | -2810.89% | -2385.96% | -3328.28% | -1608.42% | -745.51% | -337.17% | -364.24% | -466.92% |
Operating Income Growth % | -4.07% | 8.92% | -5.89% | -17.24% | -24.74% | 12.96% | 17.48% | 15.42% | 25.37% | - |
EBITDA | -19.8M | -17.97M | -18.4M | -22.09M | -28.72M | -24.36M | -20.93M | -17.42M | -12.89M | -24M |
EBITDA Margin % | -585.68% | -1028.56% | -2443.16% | -2123.75% | -3088.06% | -1454.39% | -701.91% | -312.41% | -334.54% | -447.6% |
EBITDA Growth % | -5.27% | 9.26% | -2.38% | -20.06% | -30.03% | 15.17% | 14.08% | 16.76% | 26.02% | -36.93% |
D&A (Non-Cash Add-back) | 2.15M | 2.02M | 2.77M | 2.73M | 2.23M | 2.58M | 1.3M | 1.38M | 1.14M | 1.04M |
EBIT | -20.83M | -20.78M | -18.79M | -25.94M | -30.12M | -29.59M | -21.83M | -14.74M | -13.34M | -23.39M |
Net Interest Income | 2M | 1.27M | 405K | -39K | -112K | -59K | 1.08M | 833K | 575K | -3.26M |
Interest Income | 2.13M | 1.41M | 759K | 230K | 291K | 182K | 1.25M | 957K | 2.47M | 2.05M |
Interest Expense | 129K | 141K | 354K | 269K | 403K | 241K | 171K | 124K | 1.89M | 5.32M |
Other Income/Expense | 1.12M | -793K | 2.08M | -1.36M | 521K | -2.81M | 285K | 4M | 536K | -51K |
Pretax Income | -20.83M▲ 0% | -20.78M▲ 0.2% | -19.09M▲ 8.1% | -26.17M▼ 37.1% | -30.43M▼ 16.3% | -29.75M▲ 2.2% | -21.95M▲ 26.2% | -14.81M▲ 32.5% | -13.5M▲ 8.8% | -25.09M▲ 0% |
Pretax Margin % | -616% | -1189.58% | -2535.33% | -2516.73% | -3272.26% | -1776.36% | -735.95% | -265.52% | -350.32% | -467.87% |
Income Tax | 11K | 30K | 24K | 32K | 13K | 90K | 19K | 9K | 1K | 3K |
Effective Tax Rate % | -0.05% | -0.14% | -0.13% | -0.12% | -0.04% | -0.3% | -0.09% | -0.06% | -0.01% | -0.01% |
Net Income | -20.84M▲ 0% | -20.76M▲ 0.4% | -18.11M▲ 12.7% | -23.37M▼ 29.1% | -27.79M▼ 18.9% | -26.64M▲ 4.2% | -23.88M▲ 10.4% | -16.48M▲ 31.0% | -8.48M▲ 48.5% | -13.72M▲ 0% |
Net Margin % | -616.33% | -1188.21% | -2405.31% | -2247.5% | -2988.49% | -1590.33% | -800.77% | -295.59% | -220.22% | -255.9% |
Net Income Growth % | -6.36% | 0.38% | 12.75% | -29.05% | -18.91% | 4.16% | 10.36% | 30.96% | 48.53% | 9.76% |
Net Income (Continuing) | -20.84M | -20.81M | -19.11M | -26.21M | -30.45M | -29.84M | -21.96M | -14.82M | -13.5M | -25.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | -3.99M | -3.24M | 5.67M | 984K |
Minority Interest | 0 | 253K | 10.07M | 10.84M | 9.77M | 6.86M | 16.63M | 16.29M | 12.06M | 10.54M |
EPS (Diluted) | -0.81▲ 0% | -0.81▲ 0.0% | -0.70▲ 13.6% | -0.64▲ 8.6% | -0.68▼ 6.3% | -6.46▼ 850.0% | -5.23▲ 19.0% | -2.89▲ 44.7% | -1.08▲ 62.6% | -1.41▲ 0% |
EPS Growth % | -5.19% | 0% | 13.58% | 8.57% | -6.25% | -850% | 19.04% | 44.74% | 62.63% | 48.27% |
EPS (Basic) | -0.81 | -0.81 | -0.70 | -0.64 | -0.68 | -6.46 | -5.23 | -2.89 | -1.08 | - |
Diluted Shares Outstanding | 25.73M | 25.75M | 25.75M | 36.55M | 41.01M | 4.12M | 4.57M | 5.7M | 7.87M | 9.74M |
Basic Shares Outstanding | 25.73M | 25.75M | 25.75M | 36.55M | 41.01M | 4.12M | 4.57M | 5.7M | 7.87M | 9.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EVGN Balance Sheet
Evogene Ltd. (EVGN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 72.79M | 55.49M | 49.03M | 51.82M | 56.89M | 37.75M | 34.47M | 21.59M | 15.08M | 14.96M |
Cash & Short-Term Investments | 71.75M | 54.47M | 46.88M | 48.23M | 53.87M | 35.35M | 31.06M | 15.31M | 12.99M | 13.09M |
Cash Only | 3.44M | 5.81M | 34.75M | 46.23M | 32.33M | 28.98M | 20.77M | 15.3M | 12.96M | 8.54M |
Short-Term Investments | 68.32M | 48.66M | 12.13M | 2M | 21.54M | 6.38M | 10.29M | 10K | 32K | 4.54M |
Accounts Receivable | 813K | 746K | 1.21M | 2.17M | 1.17M | 803K | 804K | 1.49M | 1.88M | 286K |
Days Sales Outstanding | 87.77 | 155.86 | 586.52 | 760.88 | 460.76 | 174.98 | 98.41 | 97.32 | 178.28 | 73.79 |
Inventory | 0 | 0 | 0 | 0 | 92K | 566K | 76K | 1.82M | 210K | 175K |
Days Inventory Outstanding | - | - | - | - | 43.78 | 227.27 | 18.62 | 278.96 | 18.72 | 60.88 |
Other Current Assets | 47K | 47K | 47K | 118K | 77K | 32K | 0 | 1.3M | -504K | 1.42M |
Total Non-Current Assets | 4.81M | 3.21M | 22.34M | 20.09M | 19.41M | 18.38M | 16.63M | 18.27M | 4.97M | 2.98M |
Property, Plant & Equipment | 4.79M | 3.19M | 5.25M | 3.94M | 4.18M | 4.07M | 3.44M | 4.25M | 2.64M | 2.41M |
Fixed Asset Turnover | 0.71x | 0.55x | 0.14x | 0.26x | 0.22x | 0.41x | 0.87x | 1.31x | 1.46x | 1.77x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 17.07M | 16.14M | 15.21M | 14.14M | 13.17M | 12.2M | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 82K | 43K | 509K |
Other Non-Current Assets | 19K | 19K | 9K | 9K | 25K | 74K | 28K | 1.75M | 2.29M | 576K |
Total Assets | 77.6M▲ 0% | 58.69M▼ 24.4% | 71.36M▲ 21.6% | 71.92M▲ 0.8% | 76.3M▲ 6.1% | 56.13M▼ 26.4% | 51.1M▼ 9.0% | 39.86M▼ 22.0% | 20.05M▼ 49.7% | 17.95M▲ 0% |
Asset Turnover | 0.04x | 0.03x | 0.01x | 0.01x | 0.01x | 0.03x | 0.06x | 0.14x | 0.19x | 0.22x |
Asset Growth % | -19.15% | -24.37% | 21.59% | 0.77% | 6.1% | -26.44% | -8.95% | -21.99% | -49.71% | -149.55% |
Total Current Liabilities | 4.66M | 5.43M | 5.75M | 9.68M | 6.88M | 5.63M | 6.94M | 18.7M | 3.44M | 5.36M |
Accounts Payable | 1.11M | 1.01M | 1M | 863K | 1.46M | 1.04M | 1.78M | 1.23M | 639K | 463K |
Days Payables Outstanding | 142.41 | 255.15 | 1.09K | 548.77 | 696.21 | 416 | 437.27 | 188.33 | 56.97 | 28.94 |
Short-Term Debt | 0 | 0 | 0 | 0 | 974K | 884K | 853K | 10.37M | 0 | 654K |
Deferred Revenue (Current) | 620K | 1.4M | 423K | 119K | 264K | 101K | 750K | 683K | 17K | 525K |
Other Current Liabilities | 0 | 0 | 0 | 4.14M | -974K | -884K | -853K | 2.88M | 1.21M | 3.3M |
Current Ratio | 15.61x | 10.22x | 8.53x | 5.36x | 8.27x | 6.71x | 4.96x | 1.15x | 4.38x | 2.79x |
Quick Ratio | 15.61x | 10.22x | 8.53x | 5.36x | 8.25x | 6.61x | 4.95x | 1.06x | 4.32x | 2.76x |
Cash Conversion Cycle | - | - | - | - | -191.67 | -13.74 | -320.24 | 187.96 | 140.04 | 105.73 |
Total Non-Current Liabilities | 3.56M | 2.96M | 5.4M | 5.36M | 6M | 15.71M | 15.47M | 6.33M | 4.63M | 1.45M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 10.11M | 10.37M | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 2.08M | 1.66M | 1.7M | 932K | 285K | 1.91M | 1.48M | 6.68M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 33K | 31K | 0 | 0 | 0 | 0 | 393K | 90K | 72K | 68K |
Total Liabilities | 8.22M | 8.39M | 11.15M | 15.03M | 12.88M | 21.34M | 22.42M | 25.03M | 5M | 6.81M |
Total Debt | 0 | 0 | 2.97M | 2.44M | 2.67M | 11.93M | 11.51M | 12.87M | 2.2M | 2.03M |
Net Debt | -3.44M | -5.81M | -31.78M | -43.79M | -29.66M | -17.05M | -9.27M | -2.43M | -10.76M | -6.51M |
Debt / Equity | - | - | 0.05x | 0.04x | 0.04x | 0.34x | 0.40x | 0.87x | 0.18x | 0.25x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.08x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.27x |
Interest Coverage | -161.45x | -147.39x | -53.08x | -96.42x | -74.73x | -122.78x | -127.67x | -118.91x | -7.05x | -4.40x |
Total Equity | 69.38M▲ 0% | 50.31M▼ 27.5% | 60.22M▲ 19.7% | 56.88M▼ 5.5% | 63.42M▲ 11.5% | 34.79M▼ 45.1% | 28.68M▼ 17.5% | 14.84M▼ 48.3% | 11.97M▼ 19.3% | 7.99M▲ 0% |
Equity Growth % | -20.52% | -27.49% | 19.7% | -5.54% | 11.49% | -45.14% | -17.55% | -48.27% | -19.3% | -51.8% |
Book Value per Share | 2.70 | 1.95 | 2.34 | 1.56 | 1.55 | 8.44 | 6.28 | 2.60 | 1.52 | 0.82 |
Total Shareholders' Equity | 69.38M | 50.05M | 50.14M | 46.05M | 53.65M | 27.93M | 12.05M | -1.45M | -82K | -2.54M |
Common Stock | 142K | 142K | 142K | 200K | 234K | 235K | 286K | 363K | 488K | 708K |
Retained Earnings | -117.03M | -137.79M | -155.9M | -179.28M | -207.07M | -233.71M | -257.59M | -274.07M | -282.56M | -288.43M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 372.54M | 187.7M | 205.9M | 225.12M | 260.49M | 261.4M | 269.35M | 272.26M | 281.99M | 285.17M |
Minority Interest | 0 | 253K | 10.07M | 10.84M | 9.77M | 6.86M | 16.63M | 16.29M | 12.06M | 10.54M |
EVGN Cash Flow Statement
Evogene Ltd. (EVGN) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -15.93M | -15.16M | -17.36M | -19.51M | -24.84M | -23.68M | -21.58M | -19.7M | -13.5M | -17.27M |
Operating CF Margin % | -471.13% | -867.83% | -2305.98% | -1876.35% | -2670.86% | -1413.61% | -723.57% | -353.24% | -350.43% | - |
Operating CF Growth % | -36.23% | 4.82% | -14.53% | -12.38% | -27.29% | 4.67% | 8.87% | 8.7% | 31.46% | 70.42% |
Net Income | -20.84M | -20.81M | -19.11M | -26.21M | -30.45M | -29.84M | -25.95M | -18.05M | -14.16M | -13.72M |
Depreciation & Amortization | 2.15M | 2.02M | 2.77M | 2.73M | 2.23M | 2.58M | 2.61M | 2.5M | 1.14M | 1.04M |
Stock-Based Compensation | 2.24M | 1.73M | 1.58M | 4.1M | 2.61M | 1.19M | 1.88M | 1.79M | 0 | 234K |
Deferred Taxes | 11K | 30K | 24K | 13K | 13K | 90K | -33K | 9K | 0 | 1K |
Other Non-Cash Items | 705K | 2.03M | -1.62M | 1.28M | -906K | 3.08M | 321K | -2.64M | 764K | -5.99M |
Working Capital Changes | -196K | -161K | -997K | -1.43M | 1.66M | -771K | -400K | -3.31M | -1.25M | 322.95K |
Change in Receivables | 37K | -28K | 88K | -150K | -59K | -67K | -1.45M | 191K | 1.71M | 1.97M |
Change in Inventory | 351K | 146K | -895K | -912K | -92K | -474K | 490K | -1.74M | -1.02M | -595.85K |
Change in Payables | -86K | -114K | -122K | -29K | 625K | -469K | 742K | -596K | -259K | -81.92K |
Cash from Investing | 15.24M | 17.35M | 37.14M | 9.41M | -20.44M | 13.27M | -4.54M | 9.62M | 17.74M | 16.79M |
Capital Expenditures | -590K | -374K | -900K | -682K | -724K | -1.17M | -785K | -626K | -135K | -21.59K |
CapEx % of Revenue | 17.45% | 21.41% | 119.52% | 65.58% | 77.85% | 69.91% | 26.32% | 11.22% | 3.5% | 0.4% |
Acquisitions | -4.76M | 0 | 10M | 0 | 0 | 0 | 0 | 0 | 78K | 105.72K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 4.76M | 0 | -10M | 0 | 0 | 0 | 26K | 58K | 17.8M | 17.89M |
Cash from Financing | 814K | 297K | 9M | 20.37M | 30.28M | 9.34M | 18.15M | 4.66M | -6.6M | -3.87M |
Debt Issued (Net) | 0 | 0 | -597K | -639K | -580K | 9.2M | -836K | -901K | -10M | -247K |
Equity Issued (Net) | 0 | 0 | 0 | 18.66M | 29.58M | 21K | 8.45M | 123K | 4.28M | 7.75M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -193K |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 814K | 297K | -97K | 2.35M | 1.27M | 125K | 10.54M | 5.43M | -885K | -11.18M |
Net Change in Cash | 199K▲ 0% | 2.38M▲ 1093.5% | 28.94M▲ 1118.4% | 11.48M▼ 60.3% | -13.9M▼ 221.1% | -3.35M▲ 75.9% | -8.21M▼ 145.4% | -5.47M▲ 33.3% | -2.35M▲ 57.1% | 1.02M▲ 0% |
Free Cash Flow | -16.52M▲ 0% | -15.54M▲ 6.0% | -18.26M▼ 17.6% | -20.2M▼ 10.6% | -25.56M▼ 26.6% | -24.85M▲ 2.8% | -22.36M▲ 10.0% | -20.33M▲ 9.1% | -13.64M▲ 32.9% | -12.08M▲ 0% |
FCF Margin % | -488.58% | -889.24% | -2425.5% | -1941.92% | -2748.71% | -1483.52% | -749.9% | -364.46% | -353.93% | -225.24% |
FCF Growth % | -32.14% | 5.96% | -17.57% | -10.58% | -26.57% | 2.79% | 10.01% | 9.1% | 32.91% | 43.5% |
FCF per Share | -0.64 | -0.60 | -0.71 | -0.55 | -0.62 | -6.03 | -4.89 | -3.57 | -1.73 | -1.24 |
FCF Conversion (FCF/Net Income) | 0.76x | 0.73x | 0.96x | 0.83x | 0.89x | 0.89x | 0.90x | 1.20x | 1.59x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EVGN Key Ratios
Evogene Ltd. (EVGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -26.6% | -34.69% | -32.78% | -39.92% | -46.21% | -54.25% | -75.24% | -75.75% | -63.29% | -110.7% |
Return on Invested Capital (ROIC) | -21.95% | -27.15% | -43.53% | -89.62% | -99.09% | -78.46% | -89.74% | -88.61% | -154.47% | -223.77% |
Gross Margin | 15.85% | 16.89% | 55.64% | 44.81% | 17.53% | 45.73% | 50.03% | 57.32% | -6.25% | -24.39% |
Net Margin | -616.33% | -1188.21% | -2405.31% | -2247.5% | -2988.49% | -1590.33% | -800.77% | -295.59% | -220.22% | -255.9% |
Debt / Equity | - | - | 0.05x | 0.04x | 0.04x | 0.34x | 0.40x | 0.87x | 0.18x | 0.25x |
Interest Coverage | -161.45x | -147.39x | -53.08x | -96.42x | -74.73x | -122.78x | -127.67x | -118.91x | -7.05x | -4.40x |
FCF Conversion | 0.76x | 0.73x | 0.96x | 0.83x | 0.89x | 0.89x | 0.90x | 1.20x | 1.59x | 0.88x |
Revenue Growth | -48.3% | -48.33% | -56.9% | 38.11% | -10.58% | 80.11% | 78.03% | 87.02% | -30.91% | -16.2% |
Related:EVGN Dividend History·EVGN Revenue History·EVGN Price History·EVGN P/E History·EVGN Financial Ratios·EVGN Institutional Holders
EVGN Frequently Asked Questions
Evogene Ltd. (EVGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evogene Ltd. (EVGN) reported $5.4M in revenue for fiscal year 2025. This represents a 69% decrease from $17.1M in 2012.
Evogene Ltd. (EVGN) saw revenue decline by 30.9% over the past year.
Evogene Ltd. (EVGN) reported a net loss of $13.7M for fiscal year 2025.
Dividend & Returns
Evogene Ltd. (EVGN) has a return on equity (ROE) of -63.3%. Negative ROE indicates the company is unprofitable.
Evogene Ltd. (EVGN) had negative free cash flow of $12.1M in fiscal year 2025, likely due to heavy capital investments.